Literature DB >> 10443550

Parkinson's disease: a major hypokinetic basal ganglia disorder.

J Sian1, M Gerlach, M B Youdim, P Riederer.   

Abstract

Disorders of the basal ganglia can be broadly divided into two: ones that manifest hypokinesia or those that elicit hyperkinesia. Parkinson's disease is the commonest form of hypokinetic disorder. The term Parkinson's disease (PD) usually encompasses idiopathic and Parkinsonian-like syndromes. PD is a chronic and progressive disease, in which the symptoms tend to appear unilateral to begin with. Subsequently subtle dysfunctions on the contralateral side may also be observed. Tremor, akinesia and rigidity are some of the classical features of the disease. Although many hypotheses have been proposed, the cause of PD largely remains obscure. Management of PD includes pharmacological treatment or/and surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443550     DOI: 10.1007/s007020050171

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  22 in total

1.  Investigating body motion patterns in patients with Parkinson's disease using matching pursuit algorithm.

Authors:  M Sekine; M Akay; T Tamura; Y Higashi; T Fujimoto
Journal:  Med Biol Eng Comput       Date:  2004-01       Impact factor: 2.602

2.  Detecting freezing of gait with a tri-axial accelerometer in Parkinson's disease patients.

Authors:  Claas Ahlrichs; Albert Samà; Michael Lawo; Joan Cabestany; Daniel Rodríguez-Martín; Carlos Pérez-López; Dean Sweeney; Leo R Quinlan; Gearòid Ò Laighin; Timothy Counihan; Patrick Browne; Lewy Hadas; Gabriel Vainstein; Alberto Costa; Roberta Annicchiarico; Sheila Alcaine; Berta Mestre; Paola Quispe; Àngels Bayes; Alejandro Rodríguez-Molinero
Journal:  Med Biol Eng Comput       Date:  2015-10-01       Impact factor: 2.602

3.  Memory Similarities Between Essential Tremor and Parkinson's Disease: A Final Common Pathway?

Authors:  Jacob A Lafo; Jacob D Jones; Michael S Okun; Russell M Bauer; Catherine C Price; Dawn Bowers
Journal:  Clin Neuropsychol       Date:  2015-12-21       Impact factor: 3.535

4.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.

Authors:  Marika Cordaro; Rosalba Siracusa; Rosalia Crupi; Daniela Impellizzeri; Alessio Filippo Peritore; Ramona D'Amico; Enrico Gugliandolo; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

Review 6.  Neurogenic erectile dysfunction.

Authors:  T F Lue
Journal:  Clin Auton Res       Date:  2001-10       Impact factor: 4.435

Review 7.  Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Authors:  Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-12-08       Impact factor: 3.921

8.  Subtle cardiovascular dysfunction in the unilateral 6-hydroxydopamine-lesioned rat.

Authors:  K Slack; R Billing; S Matthews; H N Allbutt; R Einstein; J M Henderson
Journal:  Parkinsons Dis       Date:  2010-03-21

9.  The effect of electroaucpuncture for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced proteomic changes in the mouse striatum.

Authors:  Seung-Tae Kim; Woongjoon Moon; Younbyoung Chae; Youn Jung Kim; Hyejung Lee; Hi-Joon Park
Journal:  J Physiol Sci       Date:  2009-09-18       Impact factor: 2.781

10.  Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population.

Authors:  H Niazi Shahabi; L Westberg; J Melke; A Håkansson; A Carmine Belin; O Sydow; L Olson; B Holmberg; H Nissbrandt
Journal:  J Neural Transm (Vienna)       Date:  2009-04-21       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.